• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

    Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

    ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

    ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

    Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

    Trump defends Iran war in Veterans Day address

    Nvidia preparing to oust CEO Jensen Huang: WSJ

    Pope Leo lands in Lima for Peru homecoming

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

    Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

    ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

    ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

    Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

    Trump defends Iran war in Veterans Day address

    Nvidia preparing to oust CEO Jensen Huang: WSJ

    Pope Leo lands in Lima for Peru homecoming

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

KBP’s Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration

PR Newswire by PR Newswire
13 August 2025
in PR Newswire
0
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

SINGAPORE, Aug. 13, 2025 /PRNewswire/ — KBP Biosciences Pte. Ltd. (the “Company“) today issued a statement addressing a further decision by the Singapore International Commercial Court (the “Court“) to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua (“Dr. Huang“), in support of arbitration proceedings respectively commenced by the Company and by Novo Nordisk A/S (“Novo Nordisk“).

Following the Court’s judgment today, the validity of the injunction application sought by Novo Nordisk will be determined via the arbitral process, which the Company commenced before Novo Nordisk. More importantly, in the course of judgment, the Court examined a range of issues central to the dispute, including the conduct of clinical trials and the adequacy of due diligence. The findings of the Court are subject to further scrutiny by the arbitral tribunal, which will have more time and the benefit of hearing live testimony, unlike the Court.   

1.    Independent Testimony by Steering Committee Members

The judgment cites to the independent statements from steering committee members comprising Dr. Bertram Pitt and Dr. Janet Wittes, who are highly distinguished and well respected in the field. These evidence include an open letter by Dr. Pitt and Dr. Wittes on December 18, 2024, stating that “neither [Novo] nor KBP has provided any convincing evidence that the results from [the Bulgaria site] are fraudulent”. That open letter was unavailable to the Court in the previous ex parte hearing.

Further, if the Bulgaria site were indeed tainted by serious irregularities and fraud, the “FDA and EME would have responded. However, they have not responded, and Novo did not disclose this” in the previous ex parte hearing.

2.    Statistical Errors and the Futility Determination

Eight months after it acquired Ocedurenone, Novo Nordisk terminated the clinical trials for Ocedurenone because it thought they were futile. However, Parexel International (IRL) Ltd (“Parexel“) later “informed Novo that statistical errors had been made in compiling the data”. The judgment also states that:

“The defendants submit that Novo failed to disclose errors in the Futility Determination. After the Futility Determination was made, Parexel had informed Novo that statistical errors had been made in compiling the data. After correcting for the errors, Ocedurenone satisfied only one of two futility criteria (namely, it satisfied the SBP futility criteria but not the p-value futility criteria), such that the ‘anticipated hypothesis’ is that ‘treatment effect is significant but not substantial’, and Ocedurenone was still worth ‘continuing current development plans’ and not ‘worthless’ […]”.

3.    Failure to Disclose Information and Documents Provided

The judgment highlights that Novo Nordisk had access to “a full electronic data room with documents from KBP”, which would have allowed Novo Nordisk to conduct its own analysis. These documents included “data on the vital signs of every patient enrolled in Phase 2, identifying the site they were from as well as their [systolic blood pressure (“SBP“)]”. The judgment further states that:

“The defendants allege that Novo failed to disclose the material fact that during due diligence, KBP supplied Novo with raw data in the form of the Vital Signs Data Listing and the CTA Package. Novo did not open these documents, much less request a different format for the data.”

Every pharmaceutical company has a corporate social responsibility to care for patients and address unmet medical needs.

“KBP believes that Novo Nordisk erred in stopping the development of Ocedurenone because it could help patients. KBP intends to make this proof to the tribunal,” said Dr. Huang Zhenhua, founder and chairman of the Company. 

KBP has expended significant time and resources into the development of Ocedurenone, and it remains committed to its cause. As such, the Company and Dr. Huang will strive to engage the new management to find a way forward for Ocedurenone, whilst vigorously pursuing their rights in all legal proceedings commenced, including a possible appeal from the decision of the Singapore Court.

All media inquiries can be directed to: info@kbpbiosciences.com

About KBP Biosciences

KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Singapore, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet medical needs.

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

Nanjing Offers a Window into the Yangtze River’s Cultural Heritage and Renewal

12 November 2026
International Travel Beckons, but Value Calls the Shots, Agoda Finds

International Travel Beckons, but Value Calls the Shots, Agoda Finds

12 November 2026
  • Trending
  • Comments
  • Latest

World Winter Sports Expo 2026 Opens, Charting a New Decade for Ice and Snow and Outdoor Industries

17 October 2026
Newgen reports Revenue of ₹357 crores in Q1 FY’27, up 11% Q1 YoY; Profit After Tax at ₹63 crores, up 26% Q1 YoY

Newgen Software and the Asian Institute of Digital Finance Forge Strategic Partnership to Shape the Future of Enterprise AI

10 November 2026

Volant Aerotech Secures Firm Order from Sichuan Airlines Low Altitude for VE25-100 Passenger eVTOLs

19 October 2026

Volant Aerotech Secures Firm Order from Sichuan Airlines Low Altitude for VE25-100 Passenger eVTOLs

19 October 2026
Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

12 November 2026
ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

12 November 2026

Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

12 November 2026

Trump defends Iran war in Veterans Day address

12 November 2026

Recent News

Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

Mitrade Foundation Marks First Year with Four Community Partnerships Across Asia Pacific

12 November 2026
ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

ThreatBook Named a “Strong Performer” in the Gartner® Voice of the Customer for NDR Report for the Fourth Consecutive Year

12 November 2026

Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development

12 November 2026

Trump defends Iran war in Veterans Day address

12 November 2026
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com